Altimmune (ALT)

• Market cap: $347M
• 1 day: -5.65%
• 5 days: -19.03%
• 1 month: -24.71%
• 3 months: -37.88%
• 6 months: -26.67%
• Year to date: -36.57%
• 1 year: -51.45%
• 5 years: 55.52%
• 10 years: -96.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 59

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

68% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 22

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

43% more call options, than puts

Call options by funds: $23M | Put options by funds: $16.1M

20% more capital invested

Capital invested by funds: $243M [Q3] → $292M (+$48.4M) [Q4]

7% more funds holding

Funds holding: 168 [Q3] → 180 (+12) [Q4]

1.16% more ownership

Funds ownership: 55.71% [Q3] → 56.87% (+1.16%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 166% upside
• Avg. target: $18.33 307% upside
• High target: $25 454% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 0% 1-year accuracy 0 / 41 met price target	166% upside $12	Buy Reiterated	3 Apr 2025
Citizens Capital Markets Jonathan Wolleben 67% 1-year accuracy 6 / 9 met price target	454% upside $25	Market Outperform Reiterated	2 Apr 2025
Stifel Annabel Samimy 0 / 0 met price target	299% upside $18	Buy Initiated	8 Jan 2025